WASHINGTON – The Howard University College of Pharmacy and AstraZeneca announced the creation of two new postdoctoral fellowships offering students opportunities to gain expertise in the pharmaceutical industry and in clinical settings related to cancer treatment. Two Howard students have been named inaugural fellows.
“We are excited to partner with AstraZeneca to create new opportunities for further scientific, regulatory and industrial efforts to fight cancer,” said Howard University Provost and Chief Academic Officer Anthony Wutoh, Ph.D. “The fellowship program furthers the university’s mission to develop scholars and professionals who drive change and help find solutions to today’s global problems.”
“We are so proud to create this fellowship program with Howard University and work with these exceptional students,” said Camille Hertzka, vice president and chief of AstraZeneca US Medical Affairs oncology. “AstraZeneca is committed to attracting outstanding talent and helping them develop into tomorrow’s industry leaders.”
Both two-year AstraZeneca scholarships are open to Howard University graduates and come with additional faculty appointments.
The first fellowship is for PharmD graduates and provides a six-month clinical oncology experience at Howard University Hospital and affiliated sites. This term will be followed by an 18-month immersion in AstraZeneca’s Oncology Business Unit in the US Medical Affairs team. The second fellowship is similarly structured but aimed at a Ph.D. to graduate; the two-year term includes experiences in AstraZeneca’s Oncology Business Unit in the US medical affairs team.
The inaugural PharmD Fellow in 2021, Maryland Okoro, holds a Bachelor of Science in Biochemistry, a Master of Science in Forensic Chemistry and will graduate with her PhD in Pharmacy from Howard University College of Pharmacy in May 2021.
The inaugural Ph.D. colleague, Rachel Mayaka, has a Bachelor of Science in Pharmacy, a Master of Business Administration and will have a Ph.D. in pharmaceutical sciences in May 2021 from Howard University Graduate School.
Potential candidates for future cohorts should contact dr. Earl Ettiennedirector of graduate programs and industrial partnerships at Howard University, via email at firstname.lastname@example.org or dr. Camille Popemedical director of oncology in the US, at AstraZeneca at email@example.com.
This collaboration focuses on two key fronts: the need for diverse talent at the forefront of innovation in the pharmaceutical industry and meaningfully addressing inequalities in cancer care. Howard University’s history of breaking down barriers to social justice, coupled with AstraZeneca’s track record of innovative product development, makes the perfect match, said Dr. Etienne.
“With the emergence of new therapies in oncology, the college is excited to partner with AstraZeneca to provide opportunities for graduates interested in oncology. I believe the more minority experts we have working on emerging therapies, the faster we can build trust and close the health equity gaps in different communities, Dr. Ettienne has worked diligently to bring this to fruition,” said Howard University College of Pharmacy Dean Toyin Tofade, Farm. D.
Pictured: Rachel Mayaka (left) Maryland Okoro of Howard University.
About Howard University
Founded in 1867, Howard University is a private research university made up of 13 schools and colleges. Students pursue studies in more than 120 fields leading to undergraduate, graduate and professional degrees. The university has produced four Rhodes Scholars, 10 Truman Scholars, two Marshall Scholars, more than 80 Fulbright recipients, 22 Pickering Fellows, and one Schwarzman Scholar. Howard is also producing more African American Ph.D. recipients than any other university in the United States. For more information about Howard University, call 202-238-2330, or visit the university’s website at www.howard.edu
Media Contacts: Sholnn Freeman, Howard University Office of University Communications, firstname.lastname@example.org